加载中
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
前收盘价
US$2.62
−US$0.17 · -6.09%
盘后
US$2.6555
+US$0.0355 · +1.35%
10月12日 19:45 ET
盘中时间采用ET。市场数据可能有所延迟。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日内区间
当前US$2.62
52周区间
当前US$2.62
盘中时间采用ET。市场数据可能有所延迟。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日内区间
当前US$2.62
52周区间
当前US$2.62
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1275万 USD | — | — | — | — |
| 毛利 | −1275万 USD | — | — | — | — |
| 研究与开发 | 1.32亿 USD | 2.09亿 USD | 2.2亿 USD | 2.01亿 USD | 3.06亿 USD |
| 销售、一般及管理费用 | 4429.6万 USD | 6404万 USD | 7329.9万 USD | 7156.1万 USD | 5041万 USD |
| 营业费用 | 1.78亿 USD | 2.73亿 USD | 2.93亿 USD | 2.73亿 USD | 3.57亿 USD |
| 利息收入 | 384.8万 USD | 1047.1万 USD | 993.8万 USD | 376.2万 USD | 67.6万 USD |
| 折旧和摊销 | 1275万 USD | 1550万 USD | 2455.7万 USD | 1562.5万 USD | 1107万 USD |
| 营业利润 | −1.91亿 USD | −2.73亿 USD | −2.93亿 USD | −2.73亿 USD | −3.57亿 USD |
| 净利润 | −2.44亿 USD | −2.67亿 USD | −2.83亿 USD | −2.69亿 USD | −3.56亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2419.39万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1500.35万0.15%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1258.72万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF761.22万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO444.22万0.03%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO408.15万0.02%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB399.52万0.04%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA261.56万0.01%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
